Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Non-Current Debt (2020 - 2024)

Corbus Pharmaceuticals Holdings has reported Non-Current Debt over the past 4 years, most recently at $15.9 million for Q4 2023.

  • For Q4 2023, Non-Current Debt changed 0.48% year-over-year to $15.9 million; the TTM value through Dec 2023 reached $15.9 million, changed 0.48%, while the annual FY2023 figure was $15.9 million, 0.48% changed from the prior year.
  • Non-Current Debt for Q4 2023 was $15.9 million at Corbus Pharmaceuticals Holdings, up from $11.3 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $18.6 million in Q3 2021 and troughed at $9.4 million in Q3 2022.
  • A 4-year average of $15.3 million and a median of $15.9 million in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: increased 3.89% in 2021 and later plummeted 49.4% in 2022.
  • Year by year, Non-Current Debt stood at $18.0 million in 2020, then fell by 13.27% to $15.6 million in 2021, then rose by 2.23% to $16.0 million in 2022, then dropped by 0.48% to $15.9 million in 2023.
  • Business Quant data shows Non-Current Debt for CRBP at $15.9 million in Q4 2023, $11.3 million in Q2 2023, and $14.0 million in Q1 2023.